The architecture of the active site of members of the protein tyrosine phosphatase (PTP) superfamily renders these enzymes sensitive to reversible oxidation and inactivation. The importance of reversible oxidation of PTP superfamily members in controlling the signal output following an extracellular stimulus is discussed.
Great progress has been made in defining phosphorylation-dependent signaling events that underlie physiological responses to extracellular stimuli. Although initially considered in terms of linear cascades of sequential phosphorylation reactions that culminate in a particular signaling outcome, it is now appreciated that the responses to stimuli comprise integrated networks of signaling pathways that function in a precisely coordinated manner. Control over these signaling networks is exerted at the level of both phosphorylation and dephosphorylation, catalyzed by protein kinases and phosphatases, respectively. Disturbance of this delicate balance between kinase and phosphatase activity has been shown to be a cause of human diseases including cancer, diabetes, and inflammation. Therefore, an understanding of the regulation and function of both the kinases and phosphatases in the human proteome is a prerequisite to defining the molecular mechanisms that underlie signal transduction in health and disease and ultimately to revealing opportunities for therapeutic intervention.
Phagocytic cells, such as macrophages, contain a multiprotein NADPH oxidase complex that produces a burst of reactive oxygen species (ROS) as part of the innate immune response to infection. NADPH oxidase catalyzes the single electron reduction of molecular oxygen to produce superoxide, which is rapidly converted to H 2 O 2 . A family of NADPH oxidases has now been identified in nonphagocytic cells, which produce ROS in a regulated manner at lower levels than in phagocytes, to control the signaling response to a wide variety of physiological stimuli (Lambeth, 2004) . H 2 O 2 is a small, neutral molecule that is readily produced and removed following a physiological stimulus and can freely diffuse through cellular membranes; thus, it exhibits properties that are ideal for a regulator of signaling (Finkel, 2003) . A substantial body of literature now points to the importance of regulated ROS production as a new tier of control over tyrosine phosphorylationdependent signal transduction.
Reversible Oxidation and Inactivation of PTPs
As protein tyrosine phosphatases (PTPs) have become established as critical regulators of signal transduction *Correspondence: tonks@cshl.edu in their own right, attention has been drawn to defining how the activity of these enzymes can be regulated in vivo. There are w100 human genes in the PTP superfamily, which rivals the diversity and complexity of the family of PTKs. The PTP superfamily encompasses two broad categories of enzymes: the classical pTyr-specific phosphatases and dual specificity phosphatases (DSPs), which may also dephosphorylate Ser/Thr residues, and nonprotein substrates, such as inositol phospholipids. The signature motif [I/V]HCXXGXXR[S/T], which defines the PTP superfamily, contains an invariant Cys residue, which functions as a nucleophile in catalysis. Due to the unique chemical environment of the PTP active site, this Cys residue displays an unusually low pKα, which enhances its nucleophilic properties but renders it susceptible to oxidation. Work from several labs has demonstrated that PTPs are an important target of ROS in the induction of an optimal tyrosine phosphorylation response to a variety of physiological stimuli (Rhee et al., 2003) . Oxidation of the active site Cys abrogates its nucleophilic properties, thereby inhibiting PTP activity. Thus, one function of ROS produced following agonist stimulation is to inactivate transiently the critical PTP(s) that provide an inhibitory constraint upon the system, thus facilitating the initiation of the signaling response to that stimulus. Importantly, this mode of regulation has the potential to represent a general feature of the PTP superfamily as a whole.
A key element of a signaling response is reversibility. For oxidation to represent a mechanism for reversible regulation of PTP function, it is essential that the active site Cys residue is not oxidized further than sulphenic acid (S-OH); higher oxidation to sulphinic S-O 2 H or sulphonic S-O 3 H acid is usually irreversible. A crystallographic analysis of PTP1B showed that following oxidation of the active site Cys to sulphenic acid, oxygen is rapidly eliminated to produce a cyclic sulphenamide, a 5-atom ring structure in which a covalent bond is formed between the Cys sulfur atom and the main chain nitrogen of the adjacent Ser residue (Salmeen et al., 2003; van Montfort et al., 2003) . This induces profound changes in the architecture of the active site, in which residues that are normally buried now adopt solvent-exposed positions. These structural changes, which are readily reversible in physiological reducing agents, may serve a dual purpose; to protect the enzyme from higher-order, irreversible oxidation of the active site Cys and, by exposing the oxidized Cys to cellular reducing agents, to facilitate reduction back to the active form of the enzyme. DSPs, such as cdc25 and PTEN, as well as the low Mr PTP, are also sensitive to oxidation. Unlike the classical PTPs, these enzymes contain a second Cys residue within the active site. Following oxidation of the nucleophilic cysteine within the signature motif, a disulfide bond is formed with the vicinal Cys, which protects the enzymes from higher oxidation and irreversible inactivation ( 
have shown that the timing and extent of the BCR-generated signal is determined by a feedback loop between BCR-induced Ca
2+ release and the production of ROS. They noted two, largely distinct, waves of BCR-induced phosphorylation, the first of which peaked at 1 min before declining to baseline, followed by the second, which reached a maximum by 10 min. They also showed that ligation of the BCR induced two phases of Ca 2+ mobilization, first from the ER and then via channels that promote influx of extracellular Ca 2+ . Interestingly, inhibition of Ca 2+ release from the ER attentuated both waves of phosphorylation, whereas the effects of inhibition of the second capacitative Ca 2+ influx were less pronounced. The authors concluded that the intensity of the first phase of the phosphorylation signal had a crucial impact on the extent and rate of signal progression, which focused their attention on proteins that act early in BCR signaling. (Figure 1) . As SHP-1 is known to interact directly with the BCR and attenuate signaling, it was considered as a target for BCR-induced ROS. Having confirmed the presence of SHP-1 in the BCR complex, the authors assumed, but did not formally demonstrate, that this activity was due to SHP-1. Interestingly, when they assayed the activity of the cytosolic pool of SHP-1 directly following BCR ligation, it was not inhibited, which led them to suggest that the action of ROS was restricted to the pool of SHP-1 that was associated with the BCR. In the absence of interactions with pTyr sequences in signaling receptors, the SH2 domain-containing PTPs, such as SHP-1, adopt an inactive conformation in which their active site is occluded by the N-terminal SH2 domain, blocking access to substrate, and presumably also to ROS, and rendering them inactive. Thus, it is not clear what activity the authors are measuring in these cytosolic samples. BCR stimulation also resulted in a rapid and transient inhibition of CD45, the prototypic receptor PTP, an effect that was ablated by Ca 2+ antagonists and antioxidants. It will be important to clarify exactly which PTPs are susceptible to oxidation in the BCR complex. In addition, the authors show that ROS continues to accumulate over a 5 min time course of BCR ligation, whereas maximal PTP inhibition was observed within 30 s and had returned to baseline within 1 min. It will also be of interest to define why oxidation is transient despite the continued production of ROS. Nevertheless, these data suggest that a Ca 2+ -ROS feedback loop functions like a rheostat to tune BCR signal output via reversible PTP oxidation. Despite such advances, significant challenges remain to be overcome before ROS gain universal acceptance as second messengers. Chief among these is to change the perception of ROS, such as H 2 O 2 , from agents of indiscriminate damage to specific regulators of signaling. One element of such specificity is the tight regulation of ROS production in response to a stimulus. The activity of NADPH oxidases is controlled by phosphorylation of regulatory proteins and interaction with the small GTPase RAC (Lambeth, 2004) . As described by Singh et al., another link to signaling is provided by the regulation of the Duox enzymes by Ca 2+ . Thus, we are beginning to understand at a mechanistic level how signaling and ROS production may be integrated.
Oxidation of MAP Kinase Phosphatases in TNFa-Induced Regulation of JNK
It will also be important to define precisely the source and site of ROS production and to understand how specificity of oxidation is achieved. Not all Cys residues in proteins are susceptible to H 2 O 2 , which is a relatively mild oxidant; it is only those that have a low pKα and are present in the thiolate form at neutral pH that become oxidized, in contrast to the bulk of Cys residues in proteins for which the pKα is w8. There has been considerable interest in PTPs as therapeutic targets, particularly PTP1B for diabetes and obesity. However, the highly charged active site in the native enzymes, coupled with their susceptibility to oxidation, has rendered the PTPs particularly challenging targets for drug development. The changes in conformation at the active site that accompany oxidation in vitro generate a form of the PTP in which these problematic properties are circumvented and new binding surfaces for small molecule inhibitors are presented. Therefore, assuming such structural changes are induced in vivo, stabilization of the oxidized, inactive conformation of PTP1B, for example, may potentiate insulin signaling in a similar manner to inhibiting the catalytically active form of the enzyme (analogous to stabilization of inactive p210 Bcr-Abl by Gleevec) without having to resort to some of the highly charged PTP inhibitors that have been reported to date. Also, if one assumes that oxidation targets the pool of the relevant PTP that is important for regulation of the signaling response, then this strategy will target that pool specifically, possibly also reducing complications of side effects that may accompany inhibition of the native enzyme as a whole. It will be interesting to see whether future developments in our understanding of PTP oxidation will ultimately yield new therapeutic strategies.
